Patrick G. Pilié, M.D.

Peer-Reviewed Articles

1. Hsieh KL, Chu Y, Li X, Pilie PG, Dai Y. scEMB: Learning context representation of genes based on large-scale single-cell transcriptomics. bioRxiv None(None):None, 2024. PMID: 39386549.
2. Venkatesh N, Tidwell RS, Yu Y, Aparicio A, Zurita AJ, Subudhi SK, Siddiqui BA, Mukhida SS, Gregg JR, Corn PG, Koutroumpakis E, McQuade JL, Frigo DE, Pilie PG, Huff C, Logothetis CJ, Hahn AW. Body composition in recurrent prostate cancer and the role of steroidogenic genotype. Endocr Relat Cancer None(None):None, 2024. PMID: 39324992.
3. Hahn AW, Manyam GC, Chapin BF, Zhang M, Yu Y, Pettaway CA, Chery L, Pisters LL, Ward JF, Gregg JR, Papadopoulos J, Kamat AM, Lozano M, Hoang A, Broom B, Wang X, Huff CD, Logothetis CJ, Troncoso P, Pilie PG, Davis JW. A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates. BJU Int 134(3):449-458, 2024. PMID: 38837608.
4. Hahn AW, Tidwell RS, Pilie PG, Yu Y, Liu J, Surasi DS, Titus M, Zhang J, Venkatesh N, Panaretakis T, Gregg JR, Zurita AJ, Siddiqui BA, Corn PG, Subudhi SK, Msaouel P, Koutroumpakis E, Huff CD, Aparicio A, McQuade JL, Frigo DE, Logothetis CJ. Body composition as a determinant of the therapeutic index with androgen signaling inhibition. Prostate Cancer Prostatic Dis None(None):None, 2024. PMID: 39019979.
5. Aparicio AM, Tidwell RSS, Yadav SS, Chen JS, Zhang M, Liu J, Guo S, Pilie PG, Yu Y, Song X, Vundavilli H, Jindal S, Zhu K, Viscuse PV, Lebenthal JM, Hahn AW, Soundararajan R, Corn PG, Zurita-Saavedra A, Subudhi SK, Zhang J, Wang W, Huff C, Troncoso P, Allison JP, Sharma P, Logothetis CJ. A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 30(13):2751-2763, 2024. PMID: 38683200.
6. Pilie PG, Giuliani V, Wang WL, McGrail DJ, Bristow CA, Ngoi NYL, Kyewalabye K, Wani KM, Le H, Campbell E, Sanchez NS, Yang D, Gheeya JS, Goswamy RV, Holla V, Shaw KR, Meric-Bernstam F, Liu CY, Ma X, Feng N, Machado AA, Bardenhagen JP, Vellano CP, Marszalek JR, Rajendra E, Piscitello D, Johnson TI, Likhatcheva M, Elinati E, Majithiya J, Neves J, Grinkevich V, Ranzani M, Luzarraga MR, Boursier M, Armstrong L, Geo L, Lillo G, Tse WY, Lazar AJ, Kopetz SE, Geck Do MK, Lively S, Johnson MG, Robinson HMR, Smith GCM, Carroll CL, Di Francesco ME, Jones P, Heffernan TP, Yap TA. Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types. Clin Cancer Res 30(10):2121-2139, 2024. e-Pub 2024. PMID: 38416404.
7. Viscuse, PV, Slack Tidwell, RS, Zhang, M, Rohra, P, Zhu, K, San Lucas, FA, Konnick, E, Pilie, PG, Siddiqui, BA, Logothetis, CJ, Corn, P, Subudhi, SK, Pritchard, CC, Soundararajan, R, Aparicio, A. Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments. Cancers 15(24), 2023. PMID: 38136389.
8. Wang A, Shen J, Rodriguez AA, Saunders EJ, Chen F, Janivara R, Darst BF, Sheng X, Xu Y, Chou AJ, Benlloch S, Dadaev T, Brook MN, Plym A, Sahimi A, Hoffman TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Laisk T, Figuerêdo J, Muir K, Ito S, Liu X, Project BJ, Uchio Y, Kubo M, Kamatani Y, Lophatananon A, Wan P, Andrews C, Lori A, Choudhury PP, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Giles GG, Southey MC, MacInnis RJ, Cybulski C, Wokolorczyk D, Lubinski J, Rentsch CT, Cho K, Mcmahon BH, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nordestgaard BG, Nielsen SF, Weischer M, Bojesen SE, Røder A, Stroomberg HV, Batra J, Chambers S, Horvath L, Clements JA, Tilly W, Risbridger GP, Gronberg H, Aly M, Szulkin R, Eklund M, Nordstrom T, Pashayan N, Dunning AM, Ghoussaini M, Travis RC, Key TJ, Riboli E, Park JY, Sellers TA, Lin HY, Albanes D, Weinstein S, Cook MB, Mucci LA, Giovannucci E, Lindstrom S, Kraft P, Hunter DJ, Penney KL, Turman C, Tangen CM, Goodman PJ, Thompson IM, Hamilton RJ, Fleshner NE, Finelli A, MÉ P, Stanford JL, Ostrander EA, Koutros S, Beane Freeman LE, Stampfer M, Wolk A, Håkansson N, Andriole GL, Hoover RN, Machiela MJ, Sørensen KD, Borre M, Blot WJ, Zheng W, Yeboah ED, Mensah JE, Lu YJ, Zhang HW, Feng N, Mao X, Wu Y, Zhao SC, Sun Z, Thibodeau SN, McDonnell SK, Schaid DJ, West CML, Barnett G, Maier C, Schnoeller T, Luedeke M, Kibel AS, Drake BF, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Koudou YA, John EM, Grindedal EM, Maehle L, Khaw KT, Ingles SA, Stern MC, Vega A, Gómez-Caamaño A, Fachal L, Rosenstein BS, Kerns SL, Ostrer H, Teixeira MR, Paulo P, Brandão A, Watya S, Lubwama A, Bensen JT, Butler EN, Mohler JL, Taylor JA, Kogevinas M, Dierssen-Sotos T, Castaño-Vinyals G, Cannon-Albright L, Teerlink CC, Huff CD, Pilie P, Yu Y, Bohlender RJ, Gu J, Strom SS, Multigner L, Blanchet P, Brureau L, Kaneva R, Slavov C, Mitev V, Leach RJ, Brenner H, Chen X, Holleczek B, Schöttker B, Klein EA, Hsing AW, Kittles RA, Murphy AB, Logothetis. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Nat Genet 55(12):2065-2074, 2023. e-Pub 2023. PMID: 37945903.
9. Alhalabi O, Wilson N, Xiao L, Lin Y, Khandelwal J, Moussa MJ, Msaouel P, Navai N, Gao J, Kamat AM, Pilie P, Shah AY, Goswami S, Matin S, Kovitz C, Holla V, Guo C, Czerniak B, Logothetis C, Corn PG, Dinney CPN, Campbell MT, Hansel DE, Tannir NM, Siefker-Radtke AO. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol 6(6):611-620, 2023. e-Pub 2023. PMID: 37833193.
10. Geng C, Zhang MC, Manyam GC, Vykoukal JV, Fahrmann JF, Peng S, Wu C, Park S, Kondraganti S, Wang D, Robinson BD, Loda M, Barbieri CE, Yap TA, Corn PG, Hanash S, Broom BM, Pilié PG, Thompson TC. SPOP mutations target STING1 signaling in prostate cancer and create therapeutic vulnerabilities to PARP inhibitor-induced growth suppression. Clin Cancer Res 29(21):4464-4478, 2023. e-Pub 2023. PMID: 37581614.
11. Liu XD, Zhang YT, McGrail DJ, Zhang X, Lam T, Hoang A, Hasanov E, Manyam G, Peterson CB, Zhu H, Kumar SV, Akbani R, Pilie PG, Tannir NM, Peng G, Jonasch E. SETD2 loss and ATR inhibition synergize to promote cGAS signaling and immunotherapy response in renal cell carcinoma. Clin Cancer Res 29(19):4002-4015, 2023. e-Pub 2023. PMID: 37527013.
12. Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, Cohen L, Aparicio A, Zurita AJ, Reuben A, Marmonti E, Chun SG, Reddy JP, Ghia A, McGuire S, Efstathiou E, Wang J, Wang J, Pilie P, Kovitz C, Du W, Simiele SJ, Kumar R, Borghero Y, Shi Z, Chapin B, Gomez D, Wistuba I, Corn PG. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. JAMA Oncol 9(6):825-834, 2023. e-Pub 2023. PMID: 37022702.
13. Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Pereira de Santana Gomes AJ, Roubaud G, Saad M, Zurawski B, Sakalo V, Mason GE, Francis P, Wang G, Wu D, Diorio B, Lopez-Gitlitz A, Sandhu S, Investigators MP. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol:JCO2201649. e-Pub 2023. PMID: 36952634.
14. McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Ueno NT, Ferrarotto R, Chang JT, Lin SY. Validation of cancer-type dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay. Ann Oncol 33(11):1204-1206, 2022. e-Pub 2022. PMID: 35926816.
15. Ngoi, NY, Pilie, PG, Piha-Paul, SA, Dumbrava, EE, Fu, S, Hong, DS, Karp, DD, Naing, A, Pant, S, Rodon Ahnert, J, Subbiah, V, Tsimberidou, AM, Salguero, C, Brown, CV, Hoadley, WE, Johnson, A, Yuan, Y, Westin, SN, Meric-Bernstam, F, Yap, TA. DNA Damage Response (DDR) Basket of Baskets (D-BOB) Trial. European Journal of Cancer 174:S10, 2022. PMID: None.
16. Soundararajan R, Viscuse P, Pilie P, Liu J, Logotheti S, Laberiano Fernández C, Lorenzini D, Hoang A, Lu W, Soto LMS, Wistuba II, Xu M, Song X, Shepherd PDA, Navone NM, Tidwell RSS, Lozano G, Logothetis C, Zhang J, Long JP, Estecio MR, Tzelepi V, Aparicio AM. Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) Components. Cancers (Basel) 14(13), 2022. e-Pub 2022. PMID: 35805010.
17. Li X, Dowling EK, Yan G, Dereli Z, Bozorgui B, Imanirad P, Elnaggar JH, Luna A, Menter DG, Pilié PG, Yap TA, Kopetz S, Sander C, Korkut A. Precision combination therapies based on recurrent oncogenic co-alterations. Cancer Discov 12(6):1542-1559, 2022. e-Pub 2022. PMID: 35412613.
18. Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN, Yu EY, George DJ, Chi KN, Saad F, Ståhl O, Olmos D, Danila DC, Mason GE, Espina BM, Zhao X, Urtishak KA, Francis P, Lopez-Gitlitz A, Fizazi K, investigators G. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Lancet Oncol 23(3):362-373, 2022. e-Pub 2022. PMID: 35131040.
19. Garmezy B, Gheeya J, Lin HY, Huang Y, Kim T, Jiang X, Thein KZ, Pilié PG, Zeineddine F, Wang W, Shaw KR, Rodon J, Shen JP, Yuan Y, Meric-Bernstam F, Chen K, Yap TA. Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers. JCO Precis Oncol 6:e2100267, 2022. PMID: 35108036.
20. McGrail DJ, Pilié PG, Dai H, Lam TNA, Liang Y, Voorwerk L, Kok M, Zhang XH, Rosen JM, Heimberger AB, Peterson CB, Jonasch E, Lin SY. Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers. Sci Transl Med 13(617):eabe6201, 2021. e-Pub 2021. PMID: 34705519.
21. Tang Z, Pilié PG, Geng C, Manyam GC, Yang G, Park S, Wang D, Peng S, Wu C, Peng G, Yap TA, Corn PG, Broom BM, Thompson TC. ATR inhibitor-induced CDK1-SPOP axis destabilizes PD-L1 and enhances cytotoxicity in prostate cancer. Clin Cancer Res 27(17):4898-4909, 2021. e-Pub 2021. PMID: 34168048.
22. McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Ueno NT, Ferrarotto R, Chang JT, Lin SY. Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al. Ann Oncol 32(9):1194-1197, 2021. e-Pub 2021. PMID: 34166757.
23. Wu C, Peng S, Pilié PG, Geng C, Park S, Manyam GC, Lu Y, Yang G, Tang Z, Kondraganti S, Wang D, Hudgens CW, Ledesma DA, Marques-Piubelli ML, Torres-Cabala CA, Curry JL, Troncoso P, Corn PG, Broom BM, Thompson TC. PARP and CDK4/6 inhibitor combination therapy induces apoptosis and suppresses neuroendocrine differentiation in prostate cancer. Mol Cancer Ther 20(9):1680-1691, 2021. e-Pub 2021. PMID: 34158347.
24. Elmehrath AO, Afifi AM, Al-Husseini MJ, Saad AM, Wilson N, Shohdy KS, Pilie P, Sonbol MB, Alhalabi O. Causes of Death Among Patients With Metastatic Prostate Cancer in the US From 2000 to 2016. JAMA Netw Open 4(8):e2119568, 2021. e-Pub 2021. PMID: 34351403.
25. McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Lim B, Ueno NT, Litton JK, Ferrarotto R, Chang JT, Moulder SL, Lin SY. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol 32(5):661-672, 2021. e-Pub 2021. PMID: 33736924.
26. Pilié PG, George A, Yap TA. Patient Selection Biomarker Strategies for PARP Inhibitor Therapy. Ann Oncol. e-Pub 2020. PMID: 33011228.
27. Liu XD, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, Lam T, Pilie PG, Zhu H, Beckermann KE, Haake SM, Isgandrova S, Martinez-Moczygemba M, Sahni N, Tannir NM, Lin SY, Rathmell WK, Jonasch E. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat Commun 11(1):2135, 2020. e-Pub 2020. PMID: 32358509.
28. Msaouel P, Malouf GG, Su X, Yao H, Tripathi DN, Soeung M, Gao J, Rao P, Coarfa C, Creighton CJ, Bertocchio JP, Kunnimalaiyaan S, Multani AS, Blando J, He R, Shapiro DD, Perelli L, Srinivasan S, Carbone F, Pilié PG, Karki M, Seervai RNH, Vokshi BH, Lopez-Terrada D, Cheng EH, Tang X, Lu W, Wistuba II, Thompson TC, Davidson I, Giuliani V, Schlacher K, Carugo A, Heffernan TP, Sharma P, Karam JA, Wood CG, Walker CL, Genovese G, Tannir NM. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell 37(5):720-734.e13, 2020. e-Pub 2020. PMID: 32359397.
29. Pilie P, Jonasch E. Durable complete response in renal cell carcinoma clinical trials. Lancet 393(10189):2362-2364, 2019. PMID: 31079937.
30. Pilié PG, Jonasch E. SET-ing the stage for PI3Kβ inhibitor sensitivity in clear cell renal cell carcinoma. Oncotarget 10(16):1540-1541, 2019. e-Pub 2019. PMID: 30899419.
31. Jonasch E, McCutcheon IE, Gombos DS, Ahrar K, Perrier ND, Liu D, Robichaux CC, Villarreal MF, Weldon JA, Woodson AH, Pilie PG, Fuller GN, Waguespack SG, Matin SF. Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. Lancet Oncol 19(10):1351-1359, 2018. e-Pub 2018. PMID: 30236511.
32. Pilié PG, Cooney KA. Broadening the View of Germline Mutations in Kidney Cancer. JAMA Oncol 4(9):1235-1236, 2018. e-Pub 2018. PMID: 29978199.
33. Pilié P, Hasanov E, Matin SF, Woodson AHH, Marcott VD, Bird S, Slack RS, Fuller GN, McCutcheon IE, Jonasch E. Pilot study of dovitinib in patients with von Hippel-Lindau disease. Oncotarget 9(34):23390-23395, 2018. e-Pub 2018. PMID: 29805741.
34. Pilié PG, LoRusso PM, Yap TA. Precision Medicine: Progress, Pitfalls, and Promises. Mol Cancer Ther 16(12):2641-2644, 2017. PMID: 29203693.
35. Pilié PG, Johnson AM, Hanson KL, Dayno ME, Kapron AL, Stoffel EM, Cooney KA. Germline genetic variants in men with prostate cancer and one or more additional cancers. Cancer 123(20):3925-3932, 2017. e-Pub 2017. PMID: 28657667.
36. Pilié PG, Jonasch E. Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell Carcinoma. Kidney Cancer 1(1):57-64, 2017. e-Pub 2017. PMID: 30334005.
37. Pilié PG, Jonasch E, McCutcheon IE. Key considerations in the treatment of von Hippel-Lindau disease. Future Oncol 12(15):1755-8, 2016. e-Pub 2016. PMID: 27020706.
38. Pilie PG, Giri VN, Cooney KA. HOXB13 and other high penetrant genes for prostate cancer. Asian J Androl 18(4):530-2, 2016. PMID: 27034017.
39. Bowie M, Pilie P, Wulfkuhle J, Lem S, Hoffman A, Desai S, Petricoin E, Carter A, Ambrose A, Seewaldt V, Yu D, Ibarra Drendall C. Fluoxetine induces cytotoxic endoplasmic reticulum stress and autophagy in triple negative breast cancer. World J Clin Oncol 6(6):299-311, 2015. PMID: 26677444.
40. Pilie P, Werbel WA, Riddell J, Shu X, Schaubel D, Gregg KS. Adult patients with respiratory syncytial virus infection: impact of solid organ and hematopoietic stem cell transplantation on outcomes. Transpl Infect Dis 17(4):551-7, 2015. e-Pub 2015. PMID: 26059180.
41. Ibarra-Drendall C, Troch MM, Barry WT, Broadwater G, Petricoin EF, Wulfkuhle J, Liotta LA, Lem S, Baker JC, Ford AC, Wilke LG, Zalles C, Kuderer NM, Hoffman AW, Shivraj M, Mehta P, Williams J, Tolbert N, Lee LW, Pilie PG, Yu D, Seewaldt VL. Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways. Breast Cancer Res Treat 132(2):487-98, 2012. e-Pub 2011. PMID: 21647677.
42. Pilie PG, Ibarra-Drendall C, Troch MM, Broadwater G, Barry WT, Petricoin EF, Wulfkuhle JD, Liotta LA, Lem S, Baker JC, Stouder A, Ford AC, Wilke LG, Zalles CM, Mehta P, Williams J, Shivraj M, Su Z, Geradts J, Yu D, Seewaldt VL. Protein microarray analysis of mammary epithelial cells from obese and nonobese women at high risk for breast cancer: feasibility data. Cancer Epidemiol Biomarkers Prev 20(3):476-82, 2011. e-Pub 2011. PMID: 21242333.
43. Vasilatos SN, Broadwater G, Barry WT, Baker JC, Lem S, Dietze EC, Bean GR, Bryson AD, Pilie PG, Goldenberg V, Skaar D, Paisie C, Torres-Hernandez A, Grant TL, Wilke LG, Ibarra-Drendall C, Ostrander JH, D'Amato NC, Zalles C, Jirtle R, Weaver VM, Seewaldt VL. CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis. Cancer Epidemiol Biomarkers Prev 18(3):901-14, 2009. e-Pub 2009. PMID: 19258476.
44. Baker JC, Ostrander JH, Lem S, Broadwater G, Bean GR, D'Amato NC, Goldenberg VK, Rowell C, Ibarra-Drendall C, Grant T, Pilie PG, Vasilatos SN, Troch MM, Scott V, Wilke LG, Paisie C, Rabiner SM, Torres-Hernandez A, Zalles CM, Seewaldt VL. ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention. Cancer Epidemiol Biomarkers Prev 17(8):1884-90, 2008. PMID: 18708376.
45. Bean GR, Bryson AD, Pilie PG, Goldenberg V, Baker JC, Ibarra C, Brander DM, Paisie C, Case NR, Gauthier M, Reynolds PA, Dietze E, Ostrander J, Scott V, Wilke LG, Yee L, Kimler BF, Fabian CJ, Zalles CM, Broadwater G, Tlsty TD, Seewaldt VL. Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF. Clin Cancer Res 13(22 Pt 1):6834-41, 2007. PMID: 18006786.

Other Articles

1. Ngoi NYL, Pilie PG, McGrail DJ, Zimmermann M, Schlacher K, Yap TA Targeting ATR in patients with cancer. Nat Rev Clin Oncol 21(4):278-293, 2024. PMID: 38378898.
2. Pilié PG, Gay CM, Byers LA, O'Connor MJ, Yap TA PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers. Clin Cancer Res 25(13):3759-3771, 2019. PMID: 30760478.
3. Stewart RA, Pilié PG, Yap TA Development of PARP and Immune-Checkpoint Inhibitor Combinations. Cancer Res 78(24):6717-6725, 2018. PMID: 30498083.
4. Pilié PG, Tang C, Mills GB, Yap TA State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. PMID: 30356138.

Editorials

1. Logothetis, CJ, Pilie, PG. Putting Precision Medicine in Prostate Cancer into Practice. European urology 83(2):121-124, 2023. PMID: None.

Abstracts

1. Pilié PG. PETRANHA: Phase 1/2 study of AZD5305 + novel hormonal agents in patients with metastatic prostate cancer–Interim safety and pharmacokinetic results. Journal of Clinical Oncology 42(None):None, 2024. PMID: None.
2. Pilie PG, Mcgrail D, Wang WL, Ngoi N, Kyewalabye K, Wani K, Le H, Campbell E, Holla V, Shaw KR, Meric-Bernstam F, Lazar, AJ, Giuliani V, Heffernan T, Yap TA. Ataxia-telangiectasia mutated loss of function displays variant and tissue specific differences across tumor types,. 2023 AACR Annual Meeting, 2023. PMID: None.
3. Pilie PG, Slack-Tidwell R, Viscuse PV, Subudhi SK, Corn PG, Tu S, Araujo JC, Zurita AJ, Wang J, Efstathiou E, Deinert J, Logothetis C, Thompson TC, Aparicio A. Randomized phase II study of olaparib (Ola) maintenance following cabazitaxelcarboplatin induction chemotherapy (CabCarb) in men with aggressive variant prostate cancer (AVPC). 2023 ASCO Genitourinary Cancers Symposium, 2023. PMID: None.
4. a K, Li X, Kong E, Yan G, Dereli Z, Bozorgui B, Imanirad P, Elnaggar J, Luna A, Menter D, Pilié P, Yap T, Kopetz S, Sander C. Precision combination therapies based on recurrent oncogenic co-alterations. 2022 AACR Annual Meeting, 2022. PMID: None.
5. Hahn A, Wang X, Efstathiou E, Hwang H, Zurita A, Spetsieris N, Boukovala M, Wang J, Araujo J, Pilié P, Siddiqui B, Subudhi S, Corn P, Aparicio A, Tu S, Logothetis C. Third analysis of a randomized trial of finite abiraterone acetate (AA) plus LHRH agonist (LHRHa) versus LHRHa in biochemically recurrent, non-metastatic hormone-naïve prostate cancer (M0HNPC). 2022 ASCO Genitourinary Cancers Symposium, 2022. PMID: None.
6. Viscuse PV, Zhang M, Liu J, Tidwell R, Subudhi SK, Zurita AJ, Corn PG, Tu SM, Araujo JC, Wang J, Efstathiou E, Wang J, Pilie PG, Troncoso P, Zhang J, Logothetis C, Aparicio A. Outcomes in men with metastatic castrate-resistant prostate cancer treated with early platinum-based chemotherapy following an unsatisfactory response to androgen receptor (AR) inhibition as part of the phase II dynamic allocation modular sequential (DynAMo) trial. 2021 Genitourinary Cancers Symposium, 2021. PMID: None.
7. Hahn AW, Tidwell R, Surasi DS, Pilie PG Frigo D, Subudhi SK, Efstathiou E, Zurita AJ, Tu SM, Chapin BF, Fogelman DR, SStarbuck MW, Corn PG, Aparicio A, McQuade JL, Logothetis C. Adiposity and response to androgen signaling inhibition (ASI) in men with metastatic castration-resistant prostate cancer (mCRPC). 2021 Genitourinary Cancers Symposium, 2021. PMID: None.
8. Hahn AW, Tidwell RS, Surasi DS, Msaouel P, Efstathiou E, Zurita- Saavedra AJ, Tu S, McQuade JL, Fogelman D, Starbuck MW, Subudhi SK, Corn P, Pilie PG, Aparicio A, Logothetis C. Body composition and clinical outcomes in men with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology (2020), 2020. PMID: None.
9. Gheeya JS, Goswamy R, Garmezy B, Pilie PG, Wang W, Lee S, Javle M, Rondon J, Mills Shaw KR, Meric-Bernstam F, Yap TA. Clinical characteristics and therapeutic implications of PALB2 variants in patients with advanced solid tumors. Annals of Oncology (2020), 2020. PMID: None.
10. Pilie PG, Gheeya JS, Kyewalabye K, Goswamy RV, Wani KM, Le H, Campbell E, Sanchez NS, Yang D, Garmezy B, Ileana Dumbrava E, Rodon J, Heffernan T, Holla V, Shaw KR, Meric-Bernstam F, Lazar AJ, Wang WL, Yap TA. Identifying functional loss of ATM gene in patients with advanced cancer. 2020 ASCO Virtual Scientific Program, 2020. PMID: None.
11. Viscuse PV, Zhang M, Liu J, Tidwell RS, Subudhi SK, Zurita AJ, Corn PG, Tu SM, Araujo JC, Wang J, Efstathiou E, Wang J, Pilie PG, Troncoso P, Zhang J, Logothetis C, Aparicio A. Linking the Aggressive Variant Prostate Cancer (AVPC) molecular signature (-ms) to androgen indifference in a prospective clinical trial. 2020 Genitourinary Cancers Symposium, 2020. PMID: None.
12. Garmezy B, Gheeya JS, Thein KZ, Pilie PG, Wang W, Ahnert JR, Shaw KR, Meric-Bernstam F, Yap TA. Correlation of pathogenic POLE mutations with clinical benefit to immune checkpoint inhibitor therapy. 2020 ASCO Virtual Scientific Program, 2020. PMID: None.
13. Pace A, Woodson AH, Slack-Tidwell R, Daniels MS, Pilie PG, Litton JK, Hoskovec JM, Jonasch E. Real-world outcomes of genetic testing in a GU genetics clinic and evaluation of current guidelines. 2019 Genitourinary Cancers Symposium, 2019. PMID: None.
14. Pilie P, Zhou L, Peterson CB, Peng Y, Peng G, Jonasch E. Homologous repair deficiency in VHL-mutated clear cell renal cell carcinoma. 2018 Genitourinary Cancers Symposium, 2018. PMID: None.
15. Pilie P, Mcgrail DJ, Lin SY, Jonasch E. Replication stress response deficiency (RSRD) and response to immune therapy in clear cell renal cell carcinoma (ccRCC). 2018 ASCO Annual Meeting, 2018. PMID: None.
16. Pilie P, Peterson CB, Peng Y, Zhou L, Yap TA, Peng G, Jonasch E. Functional biomarkers of homologous repair (HR) deficiency to guide novel DNA damage response targeted therapy in clear cell renal cell carcinoma (ccRCC). 2018 ASCO Annual Meeting, 2018. PMID: None.
17. Pilie PG, Zhou L, Tong P, Matin SF, Sircar K, Tamboli P, Karam JA, Wood CG, Hoang A, Jonasch E. Genomic instability and DNA damage repair in clear cell renal cell carcinoma. 2017 ASCO Annual Meeting, 2017. PMID: None.
18. Pillie PG, Matin SF, Woodson AH, Marcott VD, Bird S, Slack R, Fuller G, McCutcheon IE, Jonasch E. Pilot study of dovitinib in patients with VHL disease. 2016 Genitourinary Cancers Symposium, 2016. PMID: None.
19. Pilie P, Johnson A, Zuhlke K, Okoth L, Tomlins S, Cooney K. Identification of germline mutations in men with early onset prostate cancer. 2015 ASCO Annual Meeting, 2015. PMID: None.

Book Chapters

1. Aparicio A, Pilie PG, Surasi DS, Choi S, Chapin BF, Logothetis CJ, Corn PG. Neoplasms of the Prostate, 10th Edition. In: Holland-Frei Cancer Medicine. None. Wiley, 2023.
2. Pilie PG, Jonasch E. Hereditary Renal Cell Carcinoma. In: Rare Kidney Tumors: Comprehensive Multidisciplinary Management and Emerging Therapies. None. Springer, Cham, 2019.
3. Pilie PG. Death Receptors and Apoptosis; Cell-cycle Regulation; Tp53; RB1; CDKN2A regulation. In: Handbook of Targeted Cancer Therapy and Immunotherapy. None. Wolters Kluwer, Lippincott Williams & Wilkins, 2018.
4. Pilie PG, Milliron K, Merajver S. DCIS and Hereditary Susceptibility for Breast Cancer. In: Ductal Carcinoma In Situ and Microinvasive/Borderline Breast Cancer. None. Springer Science & Business Media, 2015.